Todd Michael Bauer
Impact in
- Oncology top 0.5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 63
- Cancer Immunotherapy and Biomarkers 19
- Lung Cancer Research Studies 15
- CAR-T cell therapy research 11
- Colorectal Cancer Treatments and Studies 9
-
- Lung Cancer Treatments and Mutations 46
- Renal cell carcinoma treatment 12
- Co-authors
- Alice Tsang Shaw (22 shared papers)Benjamin J. Solomon (26 shared papers)Enriqueta Felip (20 shared papers)Holger C. Thurm (15 shared papers)Gerson Peltz (11 shared papers)Manish R. Patel (14 shared papers)Antonello Abbattista (8 shared papers)Tony S.K. Mok (13 shared papers)
- Journals
- Annals of Oncology (36 papers)Clinical Cancer Research (11 papers)Investigational New Drugs (10 papers)Journal of Thoracic Oncology (10 papers)Journal for ImmunoTherapy of Cancer (9 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Todd Michael Bauer
151 papers receiving 11.5k citations
Todd Michael Bauer's Hit Papers
Peers
Comparison fields: 5 of 116
- Oncology 5.6k
- Pulmonary and Respiratory Medicine 5.2k
- Cancer Research 1.7k
- Biological Psychiatry 141
- Immunology 1.2k
Countries citing papers authored by Todd Michael Bauer
This map shows the geographic impact of Todd Michael Bauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Michael Bauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Michael Bauer more than expected).
Fields of papers citing papers by Todd Michael Bauer
This network shows the impact of papers produced by Todd Michael Bauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Michael Bauer. The network helps show where Todd Michael Bauer may publish in the future.
Co-authors
The 25 scholars most cited alongside Todd Michael Bauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 155 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer Hit paper breakdown → | 2020 | 804 |
| 2 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Hit paper breakdown → | 2017 | 671 |
| 3 | Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors Hit paper breakdown → | 2015 | 653 |
| 4 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study Hit paper breakdown → | 2018 | 649 |
| 5 | Efficacy of Selpercatinib in RET -Altered Thyroid Cancers Hit paper breakdown → | 2020 | 589 |
| 6 | Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial Hit paper breakdown → | 2017 | 565 |
| 7 | Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Hit paper breakdown → | 2016 | 468 |
| 8 | 2018 | 336 | |
| 9 | 2019 | 316 | |
| 10 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial Hit paper breakdown → | 2019 | 300 |
| 11 | What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) Hit paper breakdown → | 2016 | 262 |
| 12 | Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis Hit paper breakdown → | 2021 | 236 |
| 13 | 2021 | 230 | |
| 14 | 2017 | 197 | |
| 15 | 2015 | 195 | |
| 16 | 2017 | 194 | |
| 17 | 2016 | 189 | |
| 18 | Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study Hit paper breakdown → | 2024 | 188 |
| 19 | Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study Hit paper breakdown → | 2022 | 166 |
| 20 | 2018 | 153 |
About Todd Michael Bauer
Todd Michael Bauer is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Genetics, having authored 155 papers that have together received 11.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (46 papers), Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Research Studies (15 papers), Cancer Genomics and Diagnostics (12 papers), Renal cell carcinoma treatment (12 papers), CAR-T cell therapy research (11 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). The work is most often cited by research in Oncology (5.6k citations), Pulmonary and Respiratory Medicine (5.2k citations), Cancer Research (1.7k citations), Biological Psychiatry (141 citations) and Immunology (1.2k citations). Todd Michael Bauer has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Alice Tsang Shaw, Benjamin J. Solomon, Enriqueta Felip, Holger C. Thurm, Gerson Peltz, Manish R. Patel, Antonello Abbattista, Tony S.K. Mok, Anna Polli and Geoffrey Liu. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, Investigational New Drugs, Journal of Thoracic Oncology and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.